Quenching calcium

How Inozyme’s ERT could treat a broad range of calcification disorders

Inozyme Pharma Inc. is developing an enzyme replacement therapy that could be useful for a broad range of calcification disorders, and provide better efficacy and safety than off-label options.

Its sole asset, INZ-701, is a recombinant version of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme normally present throughout the body that prevents buildup of pathologic calcium deposits. ENPP1 works by hydrolyzing extracellular nucleotide triphosphates to produce the calcium-binding molecule pyrophosphate.

President and CEO Axel Bolte

Read the full 740 word article

User Sign In